Covid-19 roundup: As­traZeneca touts boost­er as ef­fec­tive against Omi­cron; Africa CDC re­port­ed­ly in talks to buy Paxlovid

Though it still hasn’t re­ceived FDA au­tho­riza­tion for its Covid-19 vac­cine, As­traZeneca is chart­ing a course for boost­er shots.

On Thurs­day, the British-Swedish phar­ma com­pa­ny re­vealed new in­for­ma­tion for its Vaxzevria shot, say­ing a boost­er dose sig­nif­i­cant­ly raised an­ti­body lev­els against Omi­cron and oth­er vari­ants, in­clud­ing Delta, re­gard­less of whether an in­di­vid­u­als’ orig­i­nal vac­cine se­ries was As­traZeneca, an mR­NA shot or Sino­vac. As­traZeneca says it plans to sub­mit the da­ta to reg­u­la­to­ry bod­ies world­wide.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER